←Back to Expert Scholars
Translational Medicine / 转化医学ADC Mechanism and Development
Philip Lowe
PhD
🏢Seagen🌐USA
Principal Scientist
30
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Philip Lowe has worked on antibody drug conjugate development across several auristatin containing programs. His contributions include optimization of drug antibody ratio and linker stability profiles. He has supported clinical development of multiple ADCs now in late stage trials. His experience spans discovery through translational medicine.
Share:
🧪Research Fields 研究领域
antibody drug conjugates
auristatin payloads
conjugation chemistry
clinical development
drug linkers
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Philip Lowe 的研究动态
Follow Philip Lowe's research updates
留下邮箱，当我们发布与 Philip Lowe（Seagen）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment